Search

Mark J Kopnitsky

from Lenhartsville, PA

Mark Kopnitsky Phones & Addresses

  • 435 Sunday Rd, Lenhartsville, PA 19534 (484) 660-3398
  • 306 Paxinosa Ave, Easton, PA 18040 (610) 438-1652
  • 321 Burke St, Easton, PA 18042 (610) 559-7540
  • Berkley, PA
  • Raritan, NJ
  • Washington, NJ
  • Baltimore, MD
  • Helotes, TX

Work

Company: Zeus scientific 1990 to Nov 1990 Position: Vice president - science and quality

Education

Degree: Bachelors, Bachelor of Science School / High School: Shippensburg University of Pennsylvania Specialities: Biology, Education

Industries

Hospital & Health Care

Resumes

Resumes

Mark Kopnitsky Photo 1

Mark Kopnitsky

View page
Location:
435 Sunday Rd, Lenhartsville, PA 19534
Industry:
Hospital & Health Care
Work:
Zeus Scientific 1990 - Nov 1990
Vice President - Science and Quality
Education:
Shippensburg University of Pennsylvania
Bachelors, Bachelor of Science, Biology, Education
Clarion University of Pennsylvania
Masters, Genetics, Microbiology

Business Records

Name / Title
Company / Classification
Phones & Addresses
Mark Kopnitsky
Vice President-research And Development
Zeus Scientific Inc
Mfg Surgical/Medical Instruments
PO Box 38, Raritan, NJ 08869
200 Evans Way, Millstone, NJ 08876
(908) 526-3744, (908) 526-0776

Publications

Us Patents

Composition For Homogeneous Multiplexed Microparticle-Based Assay

View page
US Patent:
20060263836, Nov 23, 2006
Filed:
Feb 23, 2006
Appl. No.:
11/360072
Inventors:
Mark Connelly - Doylestown PA, US
Mark Kopnitsky - Easton PA, US
International Classification:
G01N 33/555
US Classification:
435007920, 436520000
Abstract:
A method and composition for the purpose of detecting and measuring analytes, such as antibodies, which are capable of binding with certain binding partners such as antigens. A homogenous assay is performed in the presence of free unbound antibodies. Such a homogeneous assay testing for specific antibodies is herein possible by defining of test subsets of microparticles having specific antigens thereon which are capable of binding with specific target antibodies. The microparticle suspension also includes at least two calibration subsets of microparticles having a binding partner thereon with at least two known levels of concentration which is capable of binding with human antibodies for the purpose of assay calibration. A verification subset of microparticles is included with another binding partner thereon at a known concentration, capable of binding with anti-human antibodies. This suspension is incubated with a human sample and then is incubated with a tagging component which is measurable for calibration and verification and finally for determining the concentration of target antibodies bound to the test subsets. A separate verification subset of microparticles is included for verifying the calibration and for yielding a correction factor therefore. A complete calibration calculation is performed for each sample being tested. Preferably, the attaching component of the tagging component is the same molecule as the first binding partner material positioned on the calibration subsets of microparticles.

Methods And Compositions Including Diagnostic Kits For The Detection Of Staphylococcus Aureus

View page
US Patent:
20110111399, May 12, 2011
Filed:
Dec 23, 2008
Appl. No.:
12/809086
Inventors:
Shawn Mark O'Hara - Richboro PA, US
Mark James Kopnitsky - Lenhartsville PA, US
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
Methods and compositions, including diagnostic kits, for the detection of (SA) and clinically important antibiotic resistant forms thereof, such as methicillin-resistant (MRSA), vancomycin-resistant (VRSA), mupirocin-resistant (mupSA), and the like, from individuals in a sample population are disclosed Also disclosed are cost effective methods and kits for bacterial sampling and analysis via inherent and expeditious SA cell disruption methods followed by Direct PCR, circumventing the need, expense and contamination πsks associated with DNA isolation methods These improved methods in conjunction with SA prevalence analysis are applied so as to eliminate the approximately 70% of samples in the human population which do not carry SA (SA negative), followed by a second more costly test for antibiotic resistant forms thereof, such as amplification to confirm for presence of MRSA or other target disease

Methods And Kits For A Color Changing Sample Diluent

View page
US Patent:
20110136244, Jun 9, 2011
Filed:
Jan 28, 2009
Appl. No.:
12/811906
Inventors:
Mark James Kopnitsky - Lenhartsville PA, US
International Classification:
G01N 33/50
G01N 21/00
US Classification:
436 86, 436164
Abstract:
The present invention provides methods and kits in assessing color change in a series of reaction mixes while providing significant improvement in the amount of non-specific binding. The method provides for a dramatic color change when incorporated into a series of assays or used in an individual reaction. The color change enables quick visual tracking and verification of the addition of reaction components. Further, the color change allows for verification that an instrument is performing correctly in reagent addition during an automated assay. In one embodiment, the reaction mix is initially a yellowish color. Upon adding serum or plasma, the resulting solution undergoes a dramatic color change to blue-purple, allowing for easy visual verification. Color change depends upon pH shifts in the sample preparation upon addition of serum or plasma. The method is useful whenever two or more reagents are combined and confirmation of the combination is required.

Methods For Diagnosis And Assessment Of Autoimmune Disorders

View page
US Patent:
20120040850, Feb 16, 2012
Filed:
Sep 9, 2009
Appl. No.:
13/062692
Inventors:
Mark Kopnitsky - Lenhartsville PA, US
International Classification:
C40B 30/04
US Classification:
506 9
Abstract:
The present invention relates to methods and compositions for use in the diagnosis, assessment and treatment of patients with suspected autoimmune disorders. In particular, the present invention provides an auto-antibody assessment system that combines a multiplex bead array using purified antigens with human cells. When analysis is performed with the system using means such as flow cytometry, this mixture can provide a more comprehensive auto-antigen profile for assessing disease states in autoimmune disorders.

Method And Composition For Homogeneous Multiplexed Microparticle-Based Assay

View page
US Patent:
7674632, Mar 9, 2010
Filed:
Nov 15, 2002
Appl. No.:
10/295118
Inventors:
Mark Carle Connelly - Doylestown PA, US
Mark Kopnitsky - Easton PA, US
Assignee:
Zeus Scientific, Inc - Branchburg NJ
International Classification:
G01N 33/553
G01N 33/53
US Classification:
436525, 436518, 436526, 436 8, 435 72, 435 77, 435 78
Abstract:
A method and composition for detecting and measuring analytes, such as antibodies, which are capable of binding with certain binding partners such as antigens. A homogenous assay is performed in the presence of free unbound antibodies. Such a homogeneous assay testing for specific antibodies is herein possible by defining of test subsets of microparticles having specific antigens thereon which are capable of binding with specific target antibodies. The microparticle suspension also includes at least two calibration subsets of microparticles having a binding partner thereon with at least two known levels of concentration which is capable of binding with human antibodies for the purpose of assay calibration. A verification subset of microparticles is included with another binding partner thereon at a known concentration, capable of binding with anti-human antibodies. This suspension is incubated with a human sample and then is incubated with a tagging component.
Mark J Kopnitsky from Lenhartsville, PA Get Report